Identification of Complete Hydatidiform Mole Pregnancy–Associated MicroRNAs in Plasma

Hasegawa, Yoshihiro; Miura, Kiyonori; Furuya, Kenichi; Yoshiura, Koh-ichiro; Masuzaki, Hiroaki

doi:10.1373/clinchem.2013.206391

Cited by 21 publications

(25 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cell-free RNA is stable in plasma samples 40,41 ; therefore, cell-free plasma samples were prepared from maternal blood using a double centrifugation method as described previously. [26][27][28][29]31 Briefly, after the first centrifugation at 3000g for 10 minutes, the supernatant was immediately stored at À80 C. Within 6 months, plasma samples were centrifuged at 16 000g for 10 minutes and 1.2 mL of supernatant (double-centrifuged plasma sample) were used as a plasma sample for the extraction of cell-free RNA. Cell-free RNA containing small RNA molecules (ranging from 40 to 60 ng/mL) was extracted from plasma samples using the mirVana miRNA Isolation Kit (Ambion, Austin, Texas), according to the manufacturer's instructions.…”

Section: Sample Collectionmentioning

confidence: 99%

“…Each assay had a detection limit of 300 RNA copies/ mL. [26][27][28][29]31 Every batch of amplifications included 3 water blanks as negative controls for each of the reverse transcription and PCR steps. All data were collected and analyzed using a LightCycler 480 Real-Time PCR System (Roche, Pleasanton, California).…”

Section: Real-time Quantitative Reverse Transcriptionpolymerase Chainmentioning

confidence: 99%

See 1 more Smart Citation

Circulating Levels of Pregnancy-Associated, Placenta-Specific microRNAs in Pregnant Women With Placental Abruption

et al. 2017

Self Cite

View full text Add to dashboard Cite

The aim of this study was to clarify the association between circulating pregnancy-associated, placenta-specific microRNAs (miRNAs) in maternal plasma and placental abruption. All samples were obtained after receiving written informed consent, and the study protocol was approved by the institutional review board. Maternal blood samples (7 mL) were obtained at 25 to 40 weeks of gestation from 15 cases of placental abruption (placental abruption group) and from 24 cases of uncomplicated pregnancies (uncomplicated pregnancy group). The plasma concentrations of pregnancy-associated, placenta-specific miRNAs (miR-515-3p, -517a, -517c, and -518b) were measured by quantitative real-time reverse transcription-polymerase chain reaction. There were no significant differences in clinical characteristics between the 2 groups. The median concentration of plasma cell-free miR-517c in the placental abruption group was 21 672.2 copies/mL, whereas that in the uncomplicated pregnancy group was 13 452.0 copies/mL (Mann-Whitney U test, P = .047). Receiver operating characteristic curve analysis revealed that plasma cell-free miR-517c levels discriminated placental abruption from uncomplicated pregnancy with an area under the curve of 0.692. When a cutoff negative/positive value of 15 669.6 copies/mL was selected, the sensitivity and specificity were 73.3% and 62.5%, respectively. In addition, the positive and negative predictive values were 55.0% and 78.9%, respectively. Plasma cell-free miR-517a and miR-517c levels in the large abruption (degree of abruption ≥50% of placenta) group were significantly higher than in the small abruption (<50%) group ( P = .03 for both miRNAs). In conclusion, the circulating level of cell-free miR-517c in maternal plasma was increased as a consequence of placental abruption and may be a potential biomedical marker for placental abruption.

show abstract

Section: Sample Collectionmentioning

confidence: 99%

Section: Real-time Quantitative Reverse Transcriptionpolymerase Chainmentioning

confidence: 99%

Circulating Levels of Pregnancy-Associated, Placenta-Specific microRNAs in Pregnant Women With Placental Abruption

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…The real-time quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) of the miRNAs in plasma samples was performed as described previously elsewhere (5,7,13,14). Initially, 2.5 ng of RNA samples were used in the reverse transcriptase step.…”

Section: Real-time Quantitative Reverse Transcriptase Polymerase Chaimentioning

confidence: 99%

“…Each sample and each calibration dilution were analyzed in triplicate. Each assay was capable of detecting down to 300 RNA copies/mL (7,13,14). Every batch of amplifications included three water blanks as negative controls for each of the reverse transcription and PCR steps.…”

Section: Real-time Quantitative Reverse Transcriptase Polymerase Chaimentioning

confidence: 99%

Pregnancy-associated microRNAs in plasma as potential molecular markers of ectopic pregnancy

Miura

Higashijima

Mishima

et al. 2015

Fertility and Sterility

Self Cite

View full text Add to dashboard Cite

“…67,68 Implantation defects Other conditions associated with deficient or abnormal implantation include placenta previa or placenta accreta. These conditions are normally diagnosed through ultrasound imaging, although this is only moderately reliable.…”

Section: Obstetrics Expert Reviewsmentioning

confidence: 99%

Noninvasive nucleic acid–based approaches to monitor placental health and predict pregnancy-related complications

Manokhina

Wilson

Robinson

2015

American Journal of Obstetrics and Gynecology

View full text Add to dashboard Cite

During pregnancy, the placenta releases a variety of nucleic acids (including deoxyribonucleic acid, messenger ribonucleic acid, or microribonucleic acids) either as a result of cell turnover or as an active messaging system between the placenta and cells in the maternal body. The profile of released nucleic acids changes with the gestational age and has been associated with maternal and fetal parameters. It also can directly reflect pathological changes in the placenta. Nucleic acids may therefore provide a rich source of novel biomarkers for the prediction of pregnancy complications. However, their utility in the clinical setting depends, first, on overcoming some technical considerations in their quantification, and, second, on developing a better understanding of the factors that influence their function and abundance.

show abstract

Identification of Complete Hydatidiform Mole Pregnancy–Associated MicroRNAs in Plasma

Cited by 21 publications

References 5 publications

Circulating Levels of Pregnancy-Associated, Placenta-Specific microRNAs in Pregnant Women With Placental Abruption

Circulating Levels of Pregnancy-Associated, Placenta-Specific microRNAs in Pregnant Women With Placental Abruption

Pregnancy-associated microRNAs in plasma as potential molecular markers of ectopic pregnancy

Noninvasive nucleic acid–based approaches to monitor placental health and predict pregnancy-related complications

Contact Info

Product

Resources

About